Inhibrx. has filed a patent for molecules targeting 41BB, a TNF receptor superfamily member. The invention focuses on multivalent and multispecific molecules binding to 41BB. The patent claims have been canceled. GlobalData’s report on Inhibrx gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Inhibrx Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Inhibrx, Personalized cancer vaccines was a key innovation area identified from patents. Inhibrx's grant share as of January 2024 was 27%. Grant share is based on the ratio of number of grants to total number of patents.

Multispecific molecules that bind 41bb

Source: United States Patent and Trademark Office (USPTO). Credit: Inhibrx Inc

A recently filed patent (Publication Number: US20230416387A1) discloses a series of claims related to an isolated polypeptide designed for therapeutic applications. Claim 48 describes an isolated polypeptide containing VHH domains that bind to specific receptors, including 41BB, OX40, DR5, or GITR. The amino acid sequences of these VHH domains are specified in the claim, with variations allowed within certain parameters. Additionally, Claim 49 mentions the humanization of at least one VHH domain that binds to 41BB, highlighting the potential for human-specific applications.

Furthermore, the patent outlines methods for utilizing the isolated polypeptide in cancer treatment and T cell activation. Claims 59 and 61 detail the administration of the polypeptide to cancer patients to treat various types of cancer, including carcinoma, sarcoma, lymphoma, and leukemia. Additionally, Claim 61 focuses on the use of the polypeptide to increase T cell activation and proliferation, particularly in CD4+ and CD8+ T cells. The patent also emphasizes the specific amino acid sequences and configurations required for optimal functionality, underscoring the precision and specificity of the disclosed technology.

To know more about GlobalData’s detailed insights on Inhibrx, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies